Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research note released on Monday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Several other research analysts also recently issued reports on the company. Cantor Fitzgerald upped their price objective on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. HC Wainwright initiated coverage on Vanda Pharmaceuticals in a research note on Thursday, October 31st. They set a “buy” rating and a $18.00 price target on the stock.

Vanda Pharmaceuticals Trading Up 4.2 %

Shares of NASDAQ VNDA opened at $5.19 on Monday. Vanda Pharmaceuticals has a 1-year low of $3.46 and a 1-year high of $6.75. The company has a 50-day moving average of $4.82 and a two-hundred day moving average of $5.26. The company has a market cap of $302.63 million, a PE ratio of -18.54 and a beta of 0.77.

Insider Buying and Selling

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $5.17, for a total transaction of $25,850.00. Following the sale, the director now directly owns 44,857 shares in the company, valued at approximately $231,910.69. This trade represents a 10.03 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 8.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of VNDA. Meeder Asset Management Inc. acquired a new position in Vanda Pharmaceuticals during the second quarter worth $39,000. ORG Wealth Partners LLC acquired a new position in shares of Vanda Pharmaceuticals during the 3rd quarter worth about $40,000. SG Americas Securities LLC bought a new position in shares of Vanda Pharmaceuticals in the 2nd quarter valued at about $61,000. China Universal Asset Management Co. Ltd. increased its position in shares of Vanda Pharmaceuticals by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 4,374 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in Vanda Pharmaceuticals during the second quarter worth about $75,000. 88.14% of the stock is owned by institutional investors and hedge funds.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.